Ming-Kuei is a cofounder and CEO of APRINOIA. Ming-Kuei obtained his PhD in Pharmacology and Neuroscience from Boston University School of Medicine. He then completed two postdoctoral trainings at Northwestern University and Columbia University in neurophysiology, before starting his career in pharmaceutical industry. Ming-Kuei worked for Merck & CO in Boston, MA and West Point, PA, as a Senior Research Biologist for Merck’s neuroscience drug discovery laboratories, managing Alzheimer’s disease drug and biomarker discovery programs; and academic and industrial collaborations. He then moved to GlaxoSmithKline in Shanghai, as an Associate Director in GSK’s Neurodegeneration Discovery Performance Unit where he was responsible for formulating and executing therapeutic strategies for Alzheimer’s disease. Before returning to Taiwan to found APRINOIA, Ming-Kuei spent two years in MD Anderson Cancer Center in Houston, leading a newly established Alzheimer’s drug discovery consortium.